Mini review · 29 May 2024
Conference abstract
Perplex polymorphic behavior of active pharmaceutical ingredients
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Different polymorphs of the same drug substance display distinct physical properties, such as melting point, solubility, dissolution rate, hygroscopicity, stability, etc. The ability to successfully produce and reproduce specific stable polymorphs is intricately correlated with the efficiency and speed of drug development, the robustness of manufacturing process, and ? ultimately ? the stability and quality of active pharmaceutical ingredients (APIs). This paper focuses on several interesting ? and sometimes perplex ? case study examples of polymorphs ?behaving badly?. Statistically, 85% APIs exhibit (pseudo)polymorphism, and 50% of APIs have multiple (pseudo)polymorphs. The capability to effectively and consistently manufacture specific stable (pseudo)polymorphs is an integral part of the full API development process. This cannot be accomplished without a thorough and systematic process involving the polymorph discovery stage, polymorph detection, and analytical determination of the properties of the forms discovered. These nontrivial tasks are full of surprises - as in the world of polymorphs confusing results are standard. Challenging and/or unusual situations are common, such as: occurrence of forms difficult to discriminate amongst, forms difficult to detect, ?disappearing? polymorphs, isostructural forms of same and different molecules, same form but inconsistent properties for different batches, or a new, more stable form is discovered (too) late? In order to avoid late-stage development surprises, only thermodynamically most stable API forms should be developed. Frequently, such forms are discovered after a significant research and development effort. Multiple complementary techniques must be used in polymorph detection and characterization which, however, is a time-consuming and highlylabor-intensive exercise.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 26 Sep 2024
Green Chemistry for Sustainable Active Pharmaceutical Ingredients Manufacturing
Article · 5 Aug 2024
Determination and Quantification of an N-Nitroso Desmethyl Olopatadine in the Olopatadine Hydrochloride Active Pharmaceutical Ingredient by LC-MS/MS
Opinion · 3 Jun 2024
Progress in Active Pharmaceutical Ingredients (APIs): Investigating Innovative Synthesis Techniques and Regulatory Imperatives
Article · 26 Apr 2024
Determination and Quantification of an N-nitroso-Betaxolol in the Betaxolol Hydrochloride Active Pharmaceutical Ingredient by LC-MS/MS
More from this journal
The newest in Pharmaceutica Analytica Acta.
Article · 16 Sep 2026
The Fc Domains in the Monoclonal Antibody and Fusion Protein Significantly Boost the Biocomposite Suspension's Power to Combat Harmful Microorganisms, Enhance Drug Delivery, and Improve Protein Stability
Article · 26 Jun 2026
Green Pathways in Drug Quality Assessment: The Growing Role of Sustainable Pharmaceutical Analytics
Article · 26 Jun 2026
Advanced Single-Cell Signal Analysis: The Role of Ghost Cytometry in Cell Therapy Characterization
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutica Analytica Acta
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Peter H Karpinski”

